Vivo Capital, a US-China healthcare investment firm, closed a new private equity fund at an oversubscribed $635 million. The Vivo Opportunity Fund will invest in US and China small to mid-cap public life sciences companies with novel products in development. Vivo raised $750 million for its previous PE fund in 2015, and it closed a $100 million venture capital fund in 2016. The firm, which has offices in Palo Alto, Beijing, Shanghai and Taipei, now has $2.2 billion in total funds under management.
Source: China Biotoday
